How to Prevent Undeclared Alkaloid Violations in Botanical Products

When FDA analysis of a consumer product turns up an undeclared controlled alkaloid, the story that matters is not the recall itself — it's everything that went wrong upstream, before the product ever left the facility. The recent XD Investments LLC voluntary recall of Better Weather Fix Elixir products, initiated after FDA found undeclared Mitragynine and Mitragynine Pseudoindoxyl (MP) in multiple flavors and variations, is a case study worth studying carefully. Not because recalls are rare, but because this one is preventable at almost every stage.

Mitragynine Pseudoindoxyl, the more potent derivative at issue here, is not the kind of substance that slips in unnoticed under a functional quality system. If it's in your product and your label doesn't say so, one of a small number of things has gone wrong: your incoming raw material testing is absent or inadequate, your supplier qualification program has real gaps, your formulation process lacks proper controls, or some combination of all three. In my experience working with dietary supplement manufacturers over the past eight-plus years, the companies that end up in recall territory almost always got there through a slow accumulation of small compromises — not a single catastrophic failure.

This article walks through what a real prevention program looks like, using this recall as the backdrop.

Why Undeclared Kratom Alkaloids Are a High-Stakes Problem Right Now

Mitragynine is the primary active alkaloid in kratom (Mitragyna speciosa). It binds to opioid receptors and carries a well-documented risk profile. Mitragynine Pseudoindoxyl is a semi-synthetic derivative that is substantially more potent — estimated at roughly 40 times the mu-opioid receptor activity of mitragynine in some research models. The FDA has issued multiple import alerts and warning letters related to kratom products in recent years, and the substance sits in a gray zone that manufacturers of "botanical wellness" products sometimes underestimate.

According to FDA's recall announcement, approximately 448 boxes of Better Weather Fix Elixir were affected across all flavors and variations. The voluntary nature of the recall does not soften the compliance picture — FDA-initiated or voluntary, the root cause is the same.

There are currently more than 800 open dietary supplement recalls in the FDA enforcement database, and undeclared active pharmaceutical ingredients (APIs) and controlled alkaloids represent a disproportionate share of high-risk Class I and Class II events. The lesson for any botanical supplement manufacturer is that "natural" does not mean "safe from regulatory action," and "herbal" does not mean "tested."

The Regulatory Framework That Governs This: 21 CFR Part 111

The controlling regulation for dietary supplement manufacturing is 21 CFR Part 111 — Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. This is not a new rule. It has been fully phased in since 2010, and FDA has been actively enforcing it.

Here is what 21 CFR Part 111 requires that directly applies to a situation like this recall:

The critical clause for cases like this one is §111.75(a)(1): you are required to conduct at least one identity test on every lot of every component you use. Full stop. "Our supplier said it was fine" does not satisfy that requirement. A Certificate of Analysis from a supplier you haven't verified is, under FDA's framework, not evidence of anything.

What Quality Systems Would Have Caught This

Let me be direct about what I think a properly functioning quality system would have done here. There are at least four layers of control that, had any one of them been operating correctly, would likely have prevented undeclared mitragynine or its derivatives from reaching a finished product.

Layer 1: Incoming Raw Material Identity and Purity Testing

The first line of defense is your incoming material testing program. For any botanical product that could plausibly contain kratom alkaloids — whether through intentional adulteration by a supplier, cross-contamination, or mislabeling of plant material — your testing panel needs to include those alkaloids explicitly.

High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography-Mass Spectrometry (LC-MS/MS) are the methods with sufficient sensitivity and specificity to detect mitragynine and its derivatives at relevant concentrations. A general herbals screen will not catch this. You need a targeted method, validated for your matrix, run on every incoming lot before it touches your production floor.

The common failure mode I see is that companies run an identity test — often something as basic as an organoleptic check or a thin-layer chromatography screen — and call it good. That satisfies neither the spirit nor the letter of §111.75.

Layer 2: Supplier Qualification and Auditing

Under 21 CFR §111.75(a)(2), you can rely on a supplier's Certificate of Analysis to reduce your own testing frequency — but only after you have established, through your own testing, that the supplier's COAs are reliable. That's not a one-time event. It means periodic verification testing, and it means you have records demonstrating that your supplier's COA results match your own independent results across multiple lots.

A supplier qualification program worth the name includes:

• An approved supplier list with documented qualification criteria
• A questionnaire and, for high-risk ingredients, an on-site audit
• Initial qualification testing that you run, not just what the supplier provides
• Ongoing surveillance testing at a defined frequency
• A process for re-qualification when a supplier has a quality event

If your botanical ingredient is coming from a supplier you haven't visited, haven't audited, and have only verified via their own paperwork — that's a gap. In the kratom alkaloid space specifically, the adulteration risk in the supply chain is real and documented.

Layer 3: Finished Product Testing Against a Full Specification

Your finished product specification should include not only what the product is supposed to contain, but explicit limits on what it should not contain. For botanical products in the wellness category, that means negative specifications for common adulterants, including kratom alkaloids if there is any plausible exposure pathway in your ingredient sourcing.

Finished product testing is your last catch before the product goes to consumers. It is not a substitute for upstream controls, but it is a critical backstop. If your finished product test panel does not include the substances that could most plausibly show up as adulterants in your category, you have a blind spot — and FDA's lab does not have that same blind spot.

Layer 4: Formulation Review and Change Control

Any time a formula changes — a new supplier, a reformulated botanical blend, a new flavor variant — that change should trigger a documented review. Change control is not bureaucracy for its own sake; it's the mechanism that forces someone to ask whether the new ingredient or new source introduces any new risk profile.

The Better Weather Fix Elixir recall covered all flavors and variations, which suggests the issue may have been present across multiple product lines. That pattern is consistent with a supply chain problem rather than a one-off contamination event — and it's exactly the kind of thing a robust change control and supplier management process is designed to surface before the product ships.

Label Accuracy and the FDCA Section 403 Exposure

Beyond the cGMP violations, a product containing undeclared mitragynine runs directly into Section 403 of the Federal Food, Drug, and Cosmetic Act, which deems a food or supplement misbranded if its label fails to declare all ingredients accurately. That's a separate and compounding enforcement exposure on top of the adulteration issue.

There is also a 21 CFR §101.36 labeling requirement for dietary supplements that mandates the Supplement Facts panel accurately reflect the product's composition. When FDA testing finds a substance in your product that isn't on that panel, you have a misbranding violation regardless of intent.

The practical implication: even if you genuinely didn't know the alkaloid was there — even if your supplier told you it wasn't — you bear the regulatory responsibility. That's the framework. It is not forgiving about ignorance of what's in your own product.

Building a Testing Protocol That Actually Prevents This

Here is what I recommend to clients in the botanical supplement space who want to close the gaps that this kind of recall exposes.

Step 1: Map your adulterant risk by ingredient category. Not every ingredient carries the same risk of kratom alkaloid contamination. Identify which components in your supply chain come from regions or suppliers where adulteration is documented. Kratom adulteration of other botanical products — and vice versa — has been reported in the industry.

Step 2: Validate specific analytical methods. Work with a qualified third-party lab to validate LC-MS/MS methods for mitragynine, speciociliatine, paynantheine, and mitragynine pseudoindoxyl in your specific product matrix. Method validation matters — a method that works in a reference solution may not perform the same way in a complex botanical matrix.

Step 3: Test every incoming lot at a sensitivity level that matters. Your test specification should include a limit, not just a presence/absence call. Know what concentration is pharmacologically relevant and set your specification accordingly.

Step 4: Run finished product testing against the same panel. Incoming testing and finished product testing should be coordinated. If you're testing for something at the raw material stage, test for it in the finished product too — at least during initial validation of a new formula.

Step 5: Document everything. Batch records, COA reviews, test results, deviation investigations — all of it. FDA's inspection of your facility will look at your documentation as much as your process. If it isn't written down, it didn't happen.

The Supplier Conversation Most Manufacturers Avoid

One of the harder things I tell clients is that the supplier conversation they've been avoiding is one of the highest-value compliance activities they can invest in. I've seen companies accept a COA from an overseas botanical supplier for years without ever asking a pointed question about their testing methods, their own supplier chain, or their adulteration prevention controls.

That's not a relationship. It's a liability.

Suppliers that cannot answer basic questions about their own quality systems — or who push back on audit requests — are telling you something important. The question is whether you're listening before or after an FDA recall notice.

What Enforcement Patterns Tell Us About Where FDA Is Looking

FDA's enforcement data over the past three years shows a clear pattern of heightened scrutiny in the botanical supplement and "functional wellness" categories. The agency has increased laboratory sampling of products marketed with calming, mood, or pain-related claims — exactly the category that products like Better Weather Fix Elixir occupy. Import alerts covering kratom-containing products remain active, and FDA has stated repeatedly that kratom products present serious safety concerns.

According to FDA's own reporting, the agency conducted more than 400 dietary supplement facility inspections in fiscal year 2023, with cGMP violations cited in a significant majority of those inspections. Section 111 violations — particularly in the areas of component testing, specifications, and batch records — are consistently among the most frequently cited.

If your product sits in the botanical wellness space and your quality program has not been independently assessed recently, the timing here is worth paying attention to.

A Practical Compliance Checklist

For manufacturers who want to assess their current exposure against the gaps this recall illustrates:

• [ ] Do you have written identity test specifications for every incoming botanical component, including targeted alkaloid panels where relevant?
• [ ] Is your supplier qualification program documented and does it include independent verification testing?
• [ ] Do your finished product specifications include negative specifications for likely adulterants in your category?
• [ ] Is your analytical method for alkaloid testing validated for your specific matrix?
• [ ] Do you have a change control process that triggers when a supplier or ingredient source changes?
• [ ] Are your batch records complete and traceable to specific incoming lot numbers?
• [ ] When was the last time your quality system was independently audited?

If you have gaps on more than two or three of those, you're carrying compliance risk that your current testing program probably hasn't surfaced yet — and FDA's lab might.

Working With a Consultant Before FDA Comes to You

The difference between companies that catch these issues internally and companies that read about their own recalls in FDA enforcement databases is almost always a quality system that was built with serious intent and maintained consistently. That system doesn't have to be expensive or elaborate. It has to be real.

At Certify Consulting, I work with dietary supplement manufacturers — including companies in the botanical and functional wellness space — to build and audit exactly these kinds of programs. Across 200+ clients and eight-plus years of practice, the issues that drive recalls are rarely mysterious. They're predictable, and most of them are preventable. The question is whether you find them or FDA does.

If you want an independent assessment of your testing program, supplier qualification process, or overall cGMP readiness, contact Certify Consulting to start that conversation. You can also explore our dietary supplement compliance services for a fuller picture of how we approach this work.

Source: FDA recall announcement — XD Investments LLC Recalls Better Weather Fix Elixir Products Due to Undeclared Mitragynine and Mitragynine Pseudoindoxyl. Available at: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/xd-investments-llc-recalls-better-weather-fix-elixir-products-due-undeclared-mitragynine-and

Last updated: 2026-05-30